ROSSINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 41
AS - Asia 34
NA - Nord America 14
Totale 89
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 27
CN - Cina 22
US - Stati Uniti d'America 14
HK - Hong Kong 8
FR - Francia 5
SG - Singapore 3
DE - Germania 2
ES - Italia 2
IE - Irlanda 2
FI - Finlandia 1
RU - Federazione Russa 1
TW - Taiwan 1
UA - Ucraina 1
Totale 89
Salva come PNG Salva come JPEG
Città #
Arezzo 8
Hong Kong 8
Milan 5
Kent 4
West Jordan 4
Ashburn 3
Gradignan 3
Siena 3
Singapore 3
Beijing 2
Chengdu 2
Dublin 2
Madrid 2
Düsseldorf 1
Florence 1
Lappeenranta 1
Moscow 1
Nuremberg 1
Rovigo 1
Shanghai 1
Totale 56
Salva come PNG Salva come JPEG
Nome #
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation 26
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 15
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 13
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 7
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 5
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV 5
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population 5
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 3
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm 3
EGFR Amplification in Metastatic Colorectal Cancer 3
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 3
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 2
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 2
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial 2
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 2
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 2
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 2
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 2
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 2
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 2
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 2
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials 2
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 2
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 2
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 2
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 1
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 1
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: Lessons from the AtezoT RIBE study 1
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 1
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 1
Totale 121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.375
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024101 0 0 0 7 0 5 9 19 1 52 5 3
2024/202520 20 0 0 0 0 0 0 0 0 0 0 0
Totale 121